Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/11372| Title: | ASPEN: Brensocatib's role in advancing bronchiectasis management in adults through neutrophil serine protease inhibition | Authors: | O'Farrell, H. E.;Chang, A. B. | Issue Date: | 2025 | Source: | Med, 2025 (6) 9 p.100801 | Pages: | 100801 | Journal Title: | Med | Abstract: | ASPEN demonstrated that 52 weeks of once-daily brensocatib (10 mg or 25 mg), compared to placebo, significantly reduced pulmonary exacerbations among adults with bronchiectasis.(1) Additionally, time to the first exacerbation was significantly longer at the end of the 52-week treatment. Further, the decline in forced expiratory volume in 1 s was significantly lower in the 25-mg group, suggesting that brensocatib has a disease-modifying effect. | DOI: | 10.1016/j.medj.2025.100801 |
| Appears in Sites: | Children's Health Queensland Publications Queensland Health Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.